Zorevunersen (also known as STK-001) is a medication being studied for treating patients with Dravet syndrome, a rare and severe form of epilepsy. This medication is designed to reduce the frequency of major motor seizures, which include different types of seizures that affect body movement and muscle control. It works differently from traditional anti-seizure medications and is administered to help patients who experience frequent seizures.

A sham procedure (similar to a placebo but for procedures rather than medications) is used as a control in this study to compare with the active treatment.

Dravet syndrome – A rare genetic epileptic disorder that begins in the first year of life with frequent and prolonged seizures. The condition causes different types of seizures, including major motor seizures that can affect one side of the body or the entire body. Children with Dravet syndrome typically experience normal development in their first year, but then begin to show developmental delays. The condition is characterized by various seizure types, including hemiclonic, tonic-clonic, and focal seizures, which can occur multiple times per day. Dravet syndrome affects multiple aspects of a child’s development, including mobility, language, and social skills.